Notably, the VerICiguaT GlObal Study in Subjects With Heart Failure With Reduced EjectIon FrAction (VICTORIA) trial [12] recently demonstrated a 10% reduction in the composite risk of all-cause mortality or hospitalization for heart failure (HF) with Vericiguat, a soluble guanylate cyclase stimulator that enhances NO-induced sGC activation, in patients recovering from worsening HF. This evidence concerns the gene SGCB and hydrops fetalis.